IMAGE IN CARDIOLOGY

DOI: 10.4244/EIJ-D-15-00484

Spontaneous enlargement of pulmonary artery after successful balloon pulmonary angioplasty in a patient with chronic thromboembolic pulmonary hypertension

Shinya Nagayoshi1, MD; Aiko Ogawa2, MD, PhD; Hiromi Matsubara1,2*, MD, PhD

A 72-year-old woman with inoperable chronic thromboembolic pulmonary hypertension underwent balloon pulmonary angioplasty (BPA). Intravascular ultrasound (Eagle Eye® Platinum; Volcano Corp., San Diego, CA, USA) revealed severe stenosis in the right A8 with a narrow vessel distal to the lesion (Panel Aa, Panel Ab). According to a pressure wire (Primewire Prestige® PLUS; Volcano Corp.) measurement, the pulmonary artery pressure distal to the lesion was much lower than that proximal to the lesion with little pulse pressure (Panel Ac). Immediately after the dilation with a 2.5 mm balloon catheter (IKAZUCHI PAD; Kaneka, Osaka, Japan) at 14 atm, the vessel diameter distal to the lesion expanded, although the vessel diameter at the lesion was unchanged and angiographic stenosis was still observed (Panel Ba, Panel Bb). The pulmonary artery pressure distal to the lesion increased as a result of the improved blood flow (Panel Bc). Next, the right A7 and A10 were also treated. Three months later, angiographic stenosis and the blood flow improved even more, although no additional treatment was performed at the lesion. Intravascular ultrasound observations revealed dilatation of the lumen diameter and the blood flow improved (Panel Ca, Panel Cb), effectively eliminating the pressure gradient across the lesion (Panel Cc).

Increase in perfusion pressure in the pulmonary artery distal to the obstruction with partial detachment of the organised thrombi may be a driving force to dilate pulmonary arteries spontaneously over time without causing restenosis after BPA. Thus, the immediate elimination of the pressure gradient may not be necessary for the long-term success of BPA.

Conflict of interest statement

H. Matsubara has received lecture fees from GlaxoSmithKline K.K., Actelion Pharmaceuticals Japan Ltd., and Pfizer Japan Inc. The other authors have no conflicts of interest to declare.

Volume 12 Number 11
Dec 9, 2016
Volume 12 Number 11
View full issue


Key metrics

Suggested by Cory

Image – Interventional flashlight

10.4244/EIJ-D-18-01212 Oct 4, 2019
Balloon pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension
Räber L et al
free

10.4244/EIJV12SXA8 May 16, 2016
Percutaneous treatment of chronic thromboembolic pulmonary hypertension (CTEPH)
Muller DW and Liebetrau C
free
Trending articles
172.05

Focus article

10.4244/EIJY19M08_01 Jan 17, 2020
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
Glikson M et al
free
79.55

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
42

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved